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ABSTRACT
ERBB2-positive breast cancer is an aggressive disease form that can result in rapid tumor
growth and metastasis driven by the overexpression of ERBB2 growth factor receptors present
on the cell surface. Currently, approved agents can target and disable ERBB2 receptor function,
but as few as 30% of patients with disseminated ERBB2-positive breast cancer will respond to
these targeted therapeutics when given as single agents. Even then, many initial responders will
soon develop resistance to these agents. Histone deacetylase inhibitors (HDACi) are a powerful
new class of epigenetic therapeutics that have demonstrated potent antitumor activity. However,
there are several concerns that need to be addressed regarding the clinical usage of pan-HDACi
therapeutics, such as the standard clinical prototype hydroxamic acid, trichostatin-A (TSA).
These include the many genomic and non-genomic targets of pan-HDACi, the off-target side
effects, and the lack of proven HDAC-dependent cancer pathways predictive of tumor
responsiveness. Early observations in our laboratory have shown that in vitro TSA treatment of
breast cancer cell line models promotes accelerated decay of polyribosomally associated ERBB2
mRNA, calling attention to a previously unrecognized transcript decay mechanism that could be
exploited to develop new cancer therapeutics. Further studies have found that U-rich sequences
in the 3’untranslated region (UTR) of ERBB2 transcripts are an important component of this
transcript decay pathway. Based on these observations, we hypothesize that polyribosomally
associated proteins, subject to regulation by HDAC-modulated protein acetylation, bind to the
3’UTR of ERBB2 mRNA within hours of TSA treatment, and mediate its rapid degradation.
Using the ERBB2-overexpressing human breast cancer cell line SKBR3 and an ERBB2 3’UTR
mRNA construct and assay designed to precipitate protein complexes, we attempt to identify
proteins physically associated with and potentially mediating the polysome-associated ERBB2
iii

mRNA decay pathway. Progress in this effort is expected to lead to a cancer treatment strategy
more effective and selective than the use of pan-HDACi for the treatment to of ERBB2
overexpressing malignancies.

iv

ACKNOWLEDGEMENTS
This thesis was the product of countless hours of effort with the help and expertise of
several individuals that I would like to extend my deepest gratitude towards. First and foremost,
I want to thank Dr. Christopher Benz for welcoming me to his lab and being a wonderful mentor
through the past two years. Next, I would also like to thank my mentor at the lab bench, Dr. Gary
Scott, who worked by my side consistently for the past two years, making sure I was on track
and giving me a reason to smile even when the research was disheartening. Without his patience
and knowledge, I would not be the scientist equipped with the skill-set I have today. I would also
like to acknowledge another Buck Institute scientist, Dr. Birgit Schilling, and her colleagues at
the Buck Institute’s Protein Chemistry Core, who conducted the mass spectrometry analysis
described in this thesis that helped shape the results of my research.
Additionally, I would like to thank Dominican University for providing me with the
platform to advance my science education and helped me understand the biological concepts
behind some of the research I conducted. Specifically, I would like to thank Dr. Kristylea Ojeda
for being a great teacher and for serving as my second thesis advisor, as well as Dr. Maggie
Louie for guiding me through this process in her role as the Graduate Program director.
Last but not least, I would like to thank my family for their unconditional support during
the past two years in my journey to obtain my M. S. degree. I would not have been able to
achieve my higher educational goal without you.

v

TABLE OF CONTENTS
Copyright …...……….…………………………………………………………………………....i
Certification of Approval …...………………………………….………………………………...ii
Abstract …...……………………………………………………………………………………...iii
Acknowledgments…………………………………….…………………………………….....….v
Abbreviations………………………..…………….………………………………………..…...vii
Introduction………………………………………………………………………………………..1
I.
II.
III.
IV.
V.
VI.

Breast Cancer Defined
History of Breast Cancer Treatment
ERBB2 (HER2) Positive Breast Cancer
Treatment for ERBB2 (HER2) Positive Breast Cancer
HDACi as a New Therapeutic Tool
Current HDACi Research

Materials and Methods …………………………………………………………………………..17
I.
II.
III.
IV.
V.

Cell Growth, Treatment, and Harvesting of Human Breast Cancer Cell Line
Polysome Profiling
ERBB2 3’UTR mRNA Construct and Digoxigenin Labeling
RNA Immunoprecipitation
Western Blotting

Results …………………………………………………………………………………………...22
I.
II.
III.
IV.

Identification of Differential Protein Binding to the 3’UTR of ERBB2 mRNA
Establishing Sense Strand Specificity with HuR as a Positive Control
Western Blot Analysis of Protein Candidates Identified by Mass Spectrometry
hnRNP K as a Strong Candidate Mediating ERBB2 mRNA Stability

Discussion ……………………………………………………………………………………….34
References………..………………………………………………………………………………38
Appendix 1……………………………………………………………………………………….45
Appendix 2……………………………………………………………………………………….46

vi

ABBREVIATIONS
ER: Estrogen Receptor
ERBB2: Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; also referred to as HER2
(human epidermal growth factor receptor-2)
GADPH: Glyceraldehyde 3-phosphate dehydrogenase
HDAC: histone deacetylase
HDACi: histone deacetylase inhibitor
hnRNP: heteronuclear riboprotein
IP: immunoprecipitation
PR: Progesterone receptor
SKBR3: HER2 overexpressing breast adenocarcinoma cell line
TSA: trichostatin A
U: uracil
UTR: untranslated region

vii

INTRODUCTION
I.

Breast Cancer Defined
Breast cancer affects an estimated 220,000 women each year in the United States alone

(DeSantis et al., 2011). As the second leading cause of death among women in the United States,
current projections predict that one in eight women will be diagnosed with breast cancer in their
lifetime (DeSantis et al., 2011). While the exact cause cannot be pinpointed, there are certain
genetic mutations and aberrations thought to contribute to breast cancer development. Such
aberrations can either activate oncogenes or inactivate tumor suppressor genes, causing normal
cells to develop into cancerous cells (Heimann and Hellman, 2000). Today, the widespread use
of screening mammograms aides in identifying breast cancer before symptoms develop and more
widespread dissemination of metastatic disease takes place (Norman, 2005). However, breast
cancer can develop in several different forms, each with varying phenotypic and molecular
characteristics that determine both its clinical behavior and optimal treatment approach.

Figure 1. Anatomy of the Female Breast (Winslow, 2011)

The first description of breast cancer dates back between 3000-1500BC in Egyptian
papyri that detailed observations fairly consistent with modern descriptions of breast cancer
(Rayter and Manzi, 2008). Women affected with breast cancer may experience a variety of
1

symptoms, including retraction of nipple, atypical discharge from nipple, changes in skin texture,
and atypical fullness or puckering of the breast (Fig. 1; Katz and Dotters, 2007). The most
common symptom is a hard lump, usually in the upper outer corner of the breast (Katz and
Dotters, 2007). The strongest risk factors in developing breast cancer are gender and increasing
age, placing older women at higher risk for breast cancer (Emaus, 2009). Other risk factors
include high age at first birth, early menarche, late menopause, genetic predisposition, high
estrogen levels, and high breast density (Harald, 2007).
Breast cancer can be divided into clinical stages that are characterized by tumor size and
extent of the body affected. Stage 0 is referred to as carcinoma in situ, where abnormal cells are
found in the lining of a breast duct, lobules of the breast, or the nipple (Connolly et al., 2014).
Currently, carcinomas in situ are not classified as cancerous (Connolly et al., 2014). Stage I is
involvement of a tumor only within the breast, with the tumor’s maximum dimension smaller
than 2cm (Fig. 2; Chalasani et al., 2010). Stage II means that the breast tumor may have limited
spread into axillary lymph nodes but its size remains smaller than 5cm (Fig. 2; Chalasani et al.,
2010). These two stages are known as early breast cancer, which is considered highly curable
because long-term patient survival rates are high if the tumor is completely excised and treated
aggressively. The widespread use of screening mammography has been extremely important in
detecting breast cancer in these early and clinically curable stages. Stage III breast cancer
designates larger and more aggressive breast tumors that have spread to 4 or more axillary lymph
nodes or invaded either the underlying chest wall or perforated the overlying skin (Fig. 2;
Chalasani et al., 2010). Readily apparent physical changes in the composition and appearance of
the breast occur by this later stage of breast cancer (Kataja and Castiglione, 2009; Koboldt et al.,
2012). By stage IV, the breast tumor has also spread to distant organs such as the liver, lungs,
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and bones (Fig. 2; Kataja and Castiglione, 2009). 5-year survival rates dramatically decrease
from 100% for stage I breast cancers to 20% or less for newly diagnosed stage III or IV breast
cancers (Chalasani et al., 2010).

Figure 2. Illustration of the progression of breast cancer (Winslow, 2011)
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II.

History of Breast Cancer Treatment
Early stages of breast cancer can be locally treated using surgery to remove the cancerous

cells (Chalasani et al., 2010). In 1757, Henri Le Dran, a French surgeon, was the first to suggest
that surgical removal of the tumor could assist in the treatment of breast cancer, if infected
lymph nodes were removed as well (Rayter and Mansi, 2008). In 1882, William Halsted tested
Le Dran’s theory at Johns Hopkins Hospital in Baltimore, creating a new surgical technique
called radical mastectomy (Bloom and Harries, 1962). Radical mastectomy removed the breast,
axillary nodes, and chest muscles in a single procedure (Fig. 3; Bloom and Harries, 1962).
Although this treatment was the gold standard for the next century, it failed to help patients with
metastatic (stage IV) breast cancer (Rayter and Mansi, 2008).

Figure 3. Anatomical Illustration of Radical Mastectomy (Winslow, 2011)

By the end of the nineteenth century, scientific and medical advances, such as the
introduction of anesthetics, helped the advancement of breast cancer treatment (Rayter and
Mansi, 2008). George Beatson was the first to demonstrate that a portion of breast cancer
patients had a form that was hormonally dependent (Beatson, 1896). In 1895, he developed an
alternative surgical method to treat breast cancer (Beatson, 1896). He performed a bilateral
4

oophorectomy, removal of the ovary, on a woman who was diagnosed with extensive soft tissue
recurrent breast cancer, and then continued treatment with a thyroid extract (Beatson, 1896). His
treatment was a combination of surgery and endocrine therapy, which was successful in helping
this patient experience remission and 4 years of life after the procedure (Beatson, 1896). His
contribution was significant in that it demonstrated a combination of surgery and regulation of
ovarian hormones was capable of helping inhibit the development of breast cancer cells.
By the mid twentieth century, surgeons began to realize the limits in surgery alone as a
viable means of curing patients of breast cancer (Rayter and Mansi, 2008). The deformities
caused by the operations as well as the high risk of mortality made surgery an already daunting
treatment for the disease (Rayter and Mansi, 2008). In light of Beatson’s findings, physicians
began to further investigate hormone dependent growth and behavior of breast tumors. The
importance of the hormonal milieu was reinforced with development of therapies including
adrenalectomy (Huggins and Bergenstal, 1952) and hypophysectomy (Luft and Olivecrona,
1955). In a third of patients who benefited, the mechanism responsible was speculated to be
estrogen deprivation (Rayter and Mansi, 2008). This was confirmed with Jensen’s discovery of
the estrogen receptor in many breast tumors (Jensen and Jacobson, 1960). Thereafter, invasive
endocrine surgeries were superseded by the development of endocrine therapies, such as the
estrogen antagonist tamoxifen in place of oophorectomy (Jordan, 2003). In accordance,
aromatase inhibitors ultimately replaced adrenalectomy, and luteinizing hormone releasing
hormone agonists replaced hypophysectomy, resulting in the management of patients with
metastatic breast cancer by medical rather than surgical treatments (Rayter and Mansi, 2008).
In addition to these findings, some surgeons began to experiment with radiotherapy as a
form of treatment for breast cancer. Dr. Pfahler, a specialist in radiology in Philadelphia, used
5

radiotherapy on over a thousand patients with breast cancer, including many patients that were
too frail for surgery (Case, 1955). Patients with early forms of the disease had a 5-year survival
rate of 80%, demonstrating the effectiveness of this local radiotherapy approach (Case, 1955).
Dr. McWhirter of England used a combination of mastectomy with radiotherapy to the
supraclavicular, internal mammary and axillary lymph nodes in 759 patients (McWhirter, 1949).
The results indicated that a combination of the therapies resulted in higher 5-year survival rates
than either treatment alone (McWhirter, 1949). However, treatment for more aggressive forms
of breast cancer still remained a mystery for much of the twentieth century.
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III.

ERBB2 (HER2) Positive Breast Cancer
Research and clinical evidence over the past two decades have pointed to the fact that

breast cancer commonly develops into one of about 3 or 4 different clinical subtypes: luminal,
hormone receptor (ER or PR)-positive; basal-like (often referred to as triple-negative because it
lacks expression of ER, PR and ERBB2); and ERBB2 (also commonly called HER2)-positive
breast cancers (Chaudhury et al., 2010). ERBB2-positive breast cancer makes up 20-25% of all
breast cancer cases (Dent et al., 2013). ERBB2 is a member of the epidermal growth factor
receptor (EGFR) family of receptor tyrosine kinases, and the overexpression of this cell surface
growth factor receptor plays an important role in the pathogenesis of breast cancer (Fang et al.,
2014). A non-malignant mammary epithelial cell expresses about 20,000 ERBB2 receptors,
while an ERBB2-positive breast cancer cell may express 100 times the normal number of
receptors on the cell surface due to the amplification of the ErbB2 oncogene (King et al., 1985;
Kumar and Badve, 2008; Turner and Leo, 2013). This gene amplification and overexpression of
ERBB2-encoded mRNA and protein occurs early during the tumorigenic process and leads to
rapid growth and division of the transformed epithelial cells and also confers other malignant
characteristics including cell motility and invasiveness that facilitates metastatic dissemination
(Moasser, 2007; Koboldt et al., 2012). Thus, women with the ERBB2-positive subtype of breast
cancer are 11 times more likely to die from their disease (Chalasani et al., 2010).
Four tests have been developed to detect ERBB2-positive breast cancers and to
distinguish this subtype from other breast cancer subtypes. The most common is
immunohistochemistry (IHC), which measures ERBB2 protein expression on a 0 to 3+ scale: 01+ is negative, 2+ is borderline, and 3+ is ERBB2 positive (Ely and Vioral, 2007). Another
common test is fluorescence in situ hybridization (FISH). This method assesses the degree of
7

ERBB2 gene amplification found in individual cancer cells, and results are indicated as positive
or negative based on the presence of gene amplification (Ely and Vioral, 2007). A positive FISH
test signifies the presence of at least double the normal level of the oncogene in each breast
cancer cell (Kataja and Castiglione, 2009). Less common tests include the SPoT-Light ErbB2
CISH test and Inform ErbB2 Dual ISH test, which are similar to FISH in assessment of ERBB2
amplification as well as reporting a tumor as being either ERBB2/HER2 positive or negative
(Ely and Vioral, 2007). It is important to note that while these tests are used to designate a tumor
as ERBB2-positive and thereby identify the breast cancer patient as eligible to receive an antiERBB2 therapeutic, none of them can identify exactly which patients will benefit from that
targeted therapeutic agent (Emaus, 2009; Harald, 2007). Not only are newer and more effective
anti-ERBB2 therapies needed, but also needed are newer biomarkers predicting the clinical
benefit (or not) of different ERBB2-targeted agents.
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IV.

Treatment for ERBB2
B2 ((HER2) Positive Breast Cancer
The first form of treatment for ERBB2-positive breast cancers was a monoclonal

antibody, mumAb4D5, which bound specifically and tightly to the extracellular domain of the
ERBB2 receptor (Fig. 4A; Carter et al., 1992).. MumAb4D5 was shown to specifically inhibit the
growth of breast tumor-derived
derived cells line as well as facilitate immune attack against ERBB2positive cancer cells (Slamon et al., 1987). The humanized form of that murine monoclonal was
named trastuzumab, and marketed by Genentech as Herceptin
Herceptin; it went through a long process of
clinical trials before finally being approved by the FDA in 1998 (Kumar and Badve, 2008).
2008)
Many patients experienced an increase in quality and length of their lives with the use of
trastuzumab; however, a significant percent of patients with ERBB2
ERBB2-positive
positive breast cancer either
did not respond to this antibody or developed resistance to it within a year (Jackisch, 2008).
2008)

Figure 4. Various treatments for ERBB2
ERBB2-positive
ve breast cancer and their mechanism of action. A) Trastuzumab
interference with the extracellular domain of the ERBB2 receptor. B) Lapatinib interference with the intracellular
domain of ERBB2 monomers and dimers
dimers. C) Pertuzumab inhibition of the dimerization
tion of ERBB2
E
receptors. D)
Neratinib interference with the intracellular domain of ERBB2 receptors. (Park et al., 2011)
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To address clinical resistance to trastuzumab, Genentech developed another monoclonal
antibody called pertuzumab (Jackisch, 2008). It targets another epitope on the extracellular
domain of ERBB2 receptors to specifically inhibit the dimerization of ERBB2 receptors,
resulting in a more comprehensive blockade of ERBB2 signaling (Fig. 4C; Park et al., 2011).
Low molecular weight compounds have also been developed to inhibit the receptor’s
intracellular ATP binding site and thereby prevent its downstream signaling; two such agents
include Lapatinib and Neratinib (Fig. 4B and 4D; Park et al., 2011). Even with the variety of
treatments now available to disable the ERBB2 receptor function needed for the cancer cell’s
growth and metastatic spread, as few as 30% of patients with ERBB2-positive breast cancer
respond clinically to these drugs and many others later develop clinical resistance after initial
clinical response (Kute et al., 2004).
A common feature of all the above anti-ERBB2 therapeutics developed to date is that
they directly target the surface receptor protein, not any of the key signaling and downstream
tumorigenic pathways driven by overexpressed ERBB2. A novel mechanistic point of attack for
the development of a newer anti-ERBB2 therapeutic would be to target the overexpressed
ERBB2 mRNA that is translated into ERBB2 receptor protein—not simply inhibiting function of
the already encoded protein—but accelerating the cytoplasmic decay of the normally long-lived
and abundant ERBB2 mRNA produced off the amplified ERBB2 gene. Initial insight into the
feasibility of such a novel mechanistic point of attack came from our studies of histone
deacetylase (HDAC) inhibitors in ERBB2-positive breast cancer cell line models.
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V.

HDACi as a New Therapeutic Tool
In general, the dysregulation of gene expression and function leads to a combination of

genetic and epigenetic abnormalities that influence the development of breast cancer (Jones and
Baylin, 2007). A very common epigenetic abnormality during tumor development is the altered
expression of histone deacetylases (HDACs) (Ellis et al., 2009). HDACs are enzymes that
regulate gene transcription and expression by removing ε-N-acetyl lysine residues off histone
tails of chromatin and by the deacetylation of non-histone proteins (Fig. 5; Bolden et al., 2006).
The basic mechanism of acetylating histones via histone acetyl transferases (HATs) removes the
positive charge of the histones, which decreases its interaction with the negative phosphate
groups of DNA. This in effect relaxes the chromatin structure to allow for transcription.
However, HDACs oppose this activity and help maintain the closed structure of chromatin. To
influence gene transcription in normal tissue and cancerous cell lines, HDACs do not directly
bind DNA; instead, they require interaction with other proteins associated with large multiprotein complexes (Choudhary et al., 2009). Various studies have demonstrated the aberrant
expression of HDACs during tumorigenesis as well as progression to metastatic phenotypes
(Ellis et al., 2009; Glozak and Seto, 2007; Nakagawa et al., 2007; Scott et al., 2002).

Figure 5. Schematic representation of HAT, HDAC, and HDACi mechanism of action. (Todd et al., 2012)
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18 HDACs have been identified in humans and are classified into four groups (I, II, III,
and IV) based on structural differences (Fig. 6; Glozak and Seto, 2007; Chun, 2015;
Dokmanovic et al., 2007). Classes I, II, and IV require Zn2+ as a cofactor; however, class III
HDACs are sirtuins that are Zn2+ independent, and will not be considered here (deRuijter et al.,
2003; Gregoretti et al., 2004). Class I HDACs have a single catalytic site and are localized in the
nucleus, whereas class II HDACs are found in both the nucleus and cytoplasm, containing zinc
in their 1-2 catalytic sites (Dokmanovic et al., 2007). Knockout analyses of different class I and
class II HDAC proteins indicate that class I HDACs play a role in cell survival and proliferation,
while class II HDACs may have tissue-specific roles (Minucci and Pelicci, 2006). HDAC4,
HDAC6 and HDAC11 were specifically shown to be overexpressed in breast cancer tissue
(Nakagawa et al., 2007; Scott et al., 2002).

Figure 6. HDACs, their classifications, targets, and downstream signaling results as well as anticancer outcomes of
HDAC inhibition. Class I HDACs (1-3 and 8) target histone substrates in addition to transcription factors like p53.
Class II HDACs (4-11) target non-histone substrates such as SMC3 (structural maintenance of chromosomes 3),
HP1 (heterochromatin protein 1), and tubulin resulting in dysregulated cell signaling and altered transcription
activity. Implementation of HDACi results in apoptosis, senescence, cell cycle arrest, and other antitumor responses
as highlighted in the lowermost portion of the diagram. (West and Johnstone, 2014)
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Histone deacetylase inhibitors (HDACi) are a powerful new class of epigenetic
therapeutics for the treatment of various malignancies such as breast cancer. Normal cells are
relatively resistant to HDACi induced cell death; however, malignant cells have been shown to
respond well with HDACi treatment (Milos et al., 2007). The most commonly used and earliest
forms of HDACi include sodium butyrate, valproate, vorinostat, MS-275, romidepsin and
trichostatin-A (Glozak and Seto, 2007). HDACi treatment results in increased histone
acetylation, producing transcriptional activation of critical genes needed for tumor growth arrest
(Glozak and Seto, 2007). The therapeutic value of HDACi comes from findings that normal cells
are relatively resistant to HDAC inhibitor-induced cell death compared to tumor cells
(Ungerstedt et al., 2005). HDAC inhibitors are also known to modify a number of tumor related,
non-histone proteins in their pathway, producing an increase in acetylation that is associated with
several molecular processes including the inhibition of angiogenesis and the induction of
autophagy and apoptosis (Ellis et al., 2009).
HDACi can be categorized as either pan-HDACi, which target all HDACs, or classselective HDACi, which target specific classes of HDACs. The difference lies in HDACi
potency, isoform selectivity, and efficacy against various diseases (Berkley et al., 2012). In
general, pan-HDACi are more potent, but class-selective HDACi may trade potency for greater
selectivity, less toxicity and hence improved therapeutic index. However, with the many
genomic and non-genomic targets of pan-HDACi independent of the specific transcript’s
function, the off-target side effects of pan-HDACi and the lack of other proven HDACdependent cancer pathways predictive of tumor responsiveness have been major concerns that
have slowed the non-hematologic clinical development of pan-HDACi against solid tumors like
breast cancer.
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VI.

Current HDACi Research
Previous findings in our laboratory have demonstrated that 6-hour pan-HDACi treatment

(trichostatin-A or TSA) induces ERBB2 mRNA decay (Fig. 7 and 8A; Scott et al., 2002). Early
observations in our laboratory (using TSA) not only inhibits ERBB2 transcription by promoter
repression, but also induces ERBB2 protein destabilization and accelerated decay of ERBB2
transcripts (Fig. 7 and 8; Scott et al., 2002). Polysome profiling, normalized using GAPDH,
revealed that ERBB2 transcripts are concentrated in fractions 17-23, which are polyribosomally
associated (Fig. 8B and 8C). A 2-3 fold decrease in ERBB2 mRNA is observed in the same
fractions when exposed to 6-hour treatment of TSA (Fig. 8C and 8D).

Figure 7. SKBR3 human breast cancer cells probed with Stellaris FISH probes to ERBB2/HER2 mRNAs show
decrease in HER2 mRNA levels. A) Hundreds of cytoplasmic HER2 mRNA transcripts found in untreated breast
cancer cells, with multiple bright spots of active transcription within the nuclei. B) HER2 transcript levels are
markedly reduced with the addition of the HDACi TSA (trichostatin-A) as evidenced by the disappearance of both
cytoplasmic and bright nuclear spots. (Orjalo et al., 2011)
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Figure 8. HDACi induced ERBB2 mRNA decay initiates on the polyribosome. A) Northern Blot analysis
demonstrating 6-hour TSA treatment on SKBR3 cells results in decreased expression of ERBB2 mRNA relative to
GAPDH transcripts. B) Sucrose gradient (15%
(15%-40%)
40%) profiles monitored by UV absorption (A254) resolve total
cytosolic lysates into free cytosol (#1-5),
5), 40S, 60S and 80S m
monosome (#6-14),
14), and polysome (#15-24)
(#15
fractions for
subsequent Northern and Western Blotting. C) Northern blots of RNA obtained from Control (C) and TSA (T)
treated SKBR3 sucrose gradient fractions probed with ERBB2 and GAPDH relative to ethidium stained RNA gels
showing 28S, 18S, and t-RNA
RNA bands. Reduced ERBB2/GAPDH transcript ratios in T versuss C fractions confirm
that HDACi induced ERBB2 mRNA decay originates on polysomes; no ERBB2 or GAPDH transcripts were
detected in the free cytosol fractions. D) Graphical
phical representation of normalized (ERBB2/GADPH) expression
levels of ERBB2 transcripts under control and 6 hour TSA treatment conditions (Scott et al., 2002).
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ERBB2 signaling activates the PI3K/Akt/mTOR pathway, which promotes cell survival
and division, by inducing the phosphorylation of the 40s ribosomal subunit protein S6 (RPS6)
and the eukaryotic initiation factor 4e binding protein 1 (4eBP1) (Wilson-Edell et Al, 2014).
These events have been shown to stimulate polyribosome assembly and increase translation of
tumorigenic mRNAs (Thoreen et al., 2012). Preliminary findings by our laboratory show that
ERBB2 is associated with the polyribosome and that TSA induced decay of ERBB2 mRNA also
primarily occurs at the polyribosome.
Since the mechanism responsible for ERBB2 mRNA decay is unknown, these findings
led us to question the proteins involved in the ERBB2 mRNA decay pathway, specifically ones
that are polyribosomally associated. Further studies have found that U-rich sequences in the
3’untranslated region (UTR) of ERBB2 transcripts are an important component of the decay
pathway, since specific proteins are known to bind to the 3’UTR and modulate transcript
stability (Abdelmohsen, 2012; Scott et al., 2007). Based on these observations, we hypothesize
that polyribosomally associated proteins, subject to regulation by HDAC-modulated protein
acetylation, bind to the 3’UTR of ERBB2 mRNA within hours of TSA treatment and mediate its
rapid degradation. Using the ERBB2-overexpressing human breast cancer cell line SKBR3 and
an ERBB2 3’UTR mRNA construct to bind and precipitate protein complexes, we attempt to
identify proteins physically associated with and potentially mediating the polysome-associated
ERBB2 mRNA decay pathway.

16

MATERIALS AND METHODS
 Culture Growth, Treatment, and Harvesting of Human Breast Cancer Cell Line
The ERBB2-positive human breast cancer cell line, SKBR3, was obtained from
American Type Culture Collection and used in this study. The cells were grown in McCoy’s
medium (Cellgro, Manassas, VA) supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin. Experimental cells were treated with commercially obtained (SigmaAldrich, St. Louis, MO) trichostatin-A (TSA) for 2, 4, or 6 hour time periods at a concentration
of 1.5 µM. This specific concentration allows for a dynamic change in cellular activity without
killing the cell. Various time points were chosen to allow for detection of differential binding of
polyribosomal protein, with 6 hours being the maximum before cell death is induced.
Control and treated cells were harvested and dounced in a hypotonic buffer containing 50
mmol/L of Hepes (pH 7.4), 10 mmol/L of KCl, 0.3% NP40, 10 mmol/L of MgCl2, 100 Units/mL
of SUPERasein (Ambion, Grand Island, NY), and mini-complete protease inhibitors (Roche
Diagnostics, Nutley, NJ). The cell lysate was then centrifuged at 16,000 rpm for 5 minutes to
remove nuclei and other insoluble material. Cytosolic extracts were incubated with 1 to 2 mg/mL
of poly[d(I-C) in 100 mmol/L of KCl, 10 mmol/L of Tris-HCl (pH 7.5), 2 mmol/L of DTT, and
20% vol/vol glycerol at 23 C.
 Polysome Profiling
Polysome profile analysis was employed on whole cell lysates collected as described
above. The lysates were layered on top of a 10%-50% continuous sucrose gradient (Fig. 9). The
samples were then spun at 38,000 rpm for 2 hours at 4

C. The gradients were fractioned, and
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polysome fractions were then collected using the Retriever 500 with ISCO Teledyne UV/Vis
(UA6).

Figure 9. Schematic representation of poly
polysome
some profiling from formation of continuous sucrose gradient to the
polysome-profiling graph created by the ICO Teledyne UV/Vis. (Abdelmohsen, 2012)

 ERBB2 3’UTR mRNA Construct and Digoxigenin Labeling
EST clones containing 3’UTR sequence of ERBB2 were commercially obtained
(Invitrogen, Grand Island, NY) and cloned into the XbaI site of the pBluescript KS(-)
KS( vector
(Fig. 10; Stratagene, Santa Clara, CA
CA). Blunt ends were used when inserting the 3’UTR to allow
a
for the transcript to be inserted in both the forward and reverse orientation with equal
probability—forward
forward being the sense strand and reverse being the antisense strand. The vector
was linearized using a HaeIII
III digest (Sigma Aldrich, St. Louis, MO). The 3’UTR of ERBB2
E
contains an internal BstXI site at 170 bp in addition to the BstXI site12 bp upstream of the XbaI
site in the vector; thus, after the restriction enzyme disgest, the segment that is 183bp is in the
sense strand orientation and the 430bp segment produced is in the antisense orientation. The
RNA polymerase T7 used digoxigenin
digoxigenin-labeled UTP as a ribonucleoside at a 1:15 ratio (~10 U’s
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in 3’UTR of ErbB2). The labeled mRNA was then purified by Nuc Spin columns (Ambion,
Grand Island, NY) to remove any unincorporated digoxigenin. Reaction products were
electrophoretically separated on an 1.5% formaldehyde-agarose gel (0.9g of agarose, 6mL of
10X MOPS, 43mL of ddH2O, and 11mL of formaldehyde), and bands were visualized by
autoradiography to confirm orientation. RNA was subsequently denatured by a 5-minute
incubation at 65

C.

Figure 10. Schematic representation of ERBB2 3’UTR insertion into pBluescript KS(-) vector for polymerase T7
transcription using digoxigenin-labeled UTP as a ribonucleoside.

 RNA Immunoprecipitation
Denatured RNA probe was combined with different SKBR3 cytoplasmic extracts: control
extract from untreated cells and HDACi-treated extracts from cells treated with trichostatin A
(TSA) for 2, 4, or 6 hours. Cells were first heat shocked for 5 min at 37

C and then cooled at

room temp for 15 min. 0.2 µg of sheep anti-digoxigenin antibody and 12 µL of protein G
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sepharose beads (GE Healthcare, Pittsburg, PA) per milliliter of lysate were added to
cytoplasmic extracts with RNA, which were then rotated for 1.5 hours. The protein G beads from
the were washed once at 4 C in wash buffer (composed of 20 mmol/L of Tris (pH 7.4), 50
mmol/L of KCl, 10 mmol/L of MgCl2, and 0.3% NP40), resuspended in 1X loading buffer [20
mmol/L of Tris (pH 6.9), 2% SDS, 1% 2-mercaptoethanol, 50 mmol/L of NaCl, and 10%
glycerol], heated to 95 C for 10 min, and stored in a -80

C freezer (Fig. 11).

Figure 11. Schematic representation of immunoprecipitation reaction pulling down digoxigenin-labeled 3’UTR of
ERBB2 mRNA protein probe bound with complexes using Protein G beads coated in anti-digoxigenin antibody.

 Western Blotting
Equal aliquots of immunoprecipitated material were electrophoresed using NuPAGE 4%
gradient polyacrylamide gel (Invitrogen, Grand Island, NY) in 10% MES buffer for 30 minutes,
transferred at 200V to nitrocellulose (Amersham Bioscience, Pittsburgh, PA) and probed with
various antibodies (see below) in hybridization buffer (20 mmol/L of Tris (pH 7.5), 130 mmol/L
of NaCl, and 0.05% Tween 20) with 5% nonfat milk. Hybridized antibodies were visualized
using chemiluminescence, since antibodies used are labeled with chemiluminescent substrate
horseradish peroxidase (HRP). Blots were treated with SuperSignal® West Pico Stable Peroxide
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Solution and West Pico Luminol/ Enchancer solution (Cell Signaling, Beverly, MA) at a 1:1
ratio to visualize results on chemiluminescent film. The antibodies tested included HuR (mouse
3A2; Santa Cruz Biotechnology, Santa Cruz, CA), RNH1 (mouse H-135; Santa Cruz
Biotechnology, Santa Cruz, CA), CyPA (rabbit C-14; Santa Cruz Biotechnology, Santa Cruz,
CA), hnRNP K (rabbit A300-675A; Bethyl Labs, Montgomery, TX), p68 (rabbit H-144; Santa
Cruz Biotechnology, Santa Cruz, CA), and RACK1 (mouse B-3; Santa Cruz Biotechnology,
Santa Cruz, CA).
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RESULTS
I. Identification of Differential Protein Binding to 3’UTR of ERBB2 mRNA
In order to identify protein associated with the 3’UTR of ERBB2 mRNA, we created an
assay where a 3’UTR construct of ERBB2 mRNA (see Material and Methods) was placed in a
whole cell lysate to immunoprecipitate associated protein complexes. The immunoprecipitation
reaction consisted of a control cytosolic lysate and a 2-hour TSA-treated cytosolic lysate, and
both lysates were combined with the digoxigenin-labeled 3’UTR construct of ERBB2 mRNA in
both the sense and antisense orientations. The reaction pulled down digoxigenin labeled mRNA
and any bound protein complexes with it. Products of the immunoprecipitation reactions (sense
untreated, sense 2-hour TSA treated, antisense untreated, and antisense 2-hour TSA treated) were
loaded in the first four lanes of a polyacrylamide gel. Total cell lysate that was untreated as well
as treated with TSA for 2 hours was loaded in the last two lanes as indication of total protein
present. The resultant gel, stained with SyphroRuby (Invitrogen, Grand Island, NY), revealed a
multitude of protein bands in both sense and antisense stands as well as in treated and nontreated lanes (Fig. 12). The lysate lanes show a difference in total protein acetylation with 2 hour
TSA treatment. However, visual inspection could not discriminate protein bands with differential
intensity in the treated and non-treated lanes that were also specifically bound to the sense strand.
Due to this lack of sensitive resolution, specific bands were excised from the gel (Fig. 12, red
boxes) and analyzed by mass spectrometry.
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Figure 12. SyphroRuby stained gel reveals abundance of protein binding to 3’UTR of ERBB2 mRNA but with lack
of resolution to determine specific protein bands with high specificity to the sense strand versus the antisense strand.
Red boxes indicate sections of the gel excised and analyzed by mass spectrometry to identify strand specific protein
binding, while blue boxes indicate light chain and heavy chain interaction of the antibody used in the
immunoprecipitation reaction.
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Only segments of the control sense and control antisense lanes were analyzed by mass
spectrometry to help identify proteins with sense (coding) strand binding specificity to the
3’UTR of ERBB2 mRNA. Mass spectrometry identified several proteins bound to the 3’UTR of
ERBB2 in both a sense strand-specific and non-strand specific manner (Appendix 2). In order to
distinguish protein candidates for further analysis, we looked for proteins that showed at least a
two-fold preferential binding to the sense strand using a sense to antisense strand ratio. Of the
502 proteins that were identified by mass spectrometry, only 42 protein candidates met this
criterion (Appendix 1). Several of these proteins were heterogeneous nuclear ribonucleoproteins
(hnRNP), which are complexes of RNA and protein present in the cell nucleus during gene
transcription and subsequent transcriptional modification of pre-mRNA (Chaudhury et al., 2010;
Table 1). Most of these hnRNPs showed a two-fold difference in specificity to the sense strand
versus the antisense strand.

Protein
ELAV1
ROAA
ROA1
RA1L2
ROA3
HNRCL
HNRPD
HNRDL
HNRPF
HNRH1
HNRH3
ROA2
HNRPC
HNRPU
HNRPK
HNRL1

Gene

Table 1: Heteronuclear Proteins Discovered from MS Analysis
Name

ELAVL1
HNRNPAB
HNRNPA1
HNRNPA1L2
HNRNPA3
HNRNPCL1
HNRNPD
HNRNPDL
HNRNPF
HNRNPH1
HNRNPH3
HNRNPA2B1
HNRNPC
HNRNPU
HNRNPK
HNRNPUL1

ELAV-like protein 1 (HuR) [CONTROL]
Heterogeneous nuclear ribonucleoprotein A/B
Heterogeneous nuclear ribonucleoprotein A1
Heterogeneous nuclear ribonucleoprotein A1-like 2
Heterogeneous nuclear ribonucleoprotein A3
Heterogeneous nuclear ribonucleoprotein C-like 1
Heterogeneous nuclear ribonucleoprotein D0
Heterogeneous nuclear ribonucleoprotein D-like
Heterogeneous nuclear ribonucleoprotein F
Heterogeneous nuclear ribonucleoprotein H
Heterogeneous nuclear ribonucleoprotein H3
Heterogeneous nuclear ribonucleoproteins A2/B1
Heterogeneous nuclear ribonucleoproteins C1/C2
Heterogeneous nuclear ribonucleoprotein U
Heterogeneous nuclear ribonucleoprotein K
Heterogeneous nuclear ribonucleoprotein U-like protein 1

Ratio
(sense/antisense)
2.1
>1
2.8
2.8
2.9
1.9
3
3
1.2
2.2
1
4
1.9
3.8
2.7
13.4
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There were also a few strong candidates, other than hnRNP’s, present in multiple
isoforms and that had strong sense-strand specificity as identified by mass spectrometry (Table
2). The strongest non-hnRNP candidate was peptidylprolyl isomerase A (PPIA), which catalyzes
the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerates the
folding of proteins (Pliyev and Gurvits, 1999). PPIA demonstrated a 42.7times stronger
specificity to the sense strand over the antisense strand, on average of the various isoforms
detected. The other non-hnRNP candidates were probable ATP-dependent RNA helicases,
specifically DEAD box proteins characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD)
(Andreou and Lkostermeier, 2014). They are responsible for catalyzing the ATP-dependent
unwinding of RNA duplexes and accompany RNA molecules throughout their cellular life
(Andreou and Lkostermeier, 2014). Mass spectrometry analysis demonstrated, on average of the
various isoforms detected, a 4.7 fold difference in specificity to the sense strand over the
antisense strand (Table 2).

Table 2: Non-hnRNP Protein Candidates from MS Analysis (Present in Multiple Isoforms)
Precursor
Protein
Ratio
Average
(molecular weight)
(sense/antisense)
Ratio
528.27
577.79
624.32
684.87
547.78
648.33
468.77
613.86
565.33
492.76
493.29
426.72
547.28
582.30
434.22
584.86

Peptidyl-prolyl cis-trans isomerase A
Peptidyl-prolyl cis-trans isomerase A
Peptidyl-prolyl cis-trans isomerase A
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
Probable ATP-dependent RNA helicase DDX5
ATP-dependent RNA helicase DDX3X
ATP-dependent RNA helicase DDX3X
ATP-dependent RNA helicase DDX3X
ATP-dependent RNA helicase DDX3X
ATP-dependent RNA helicase DDX3X

27.5
47.9
58.9
11.1
6.4
3.4
2.5
4.2
9.9
2.2
4.1
2.1
2.1
1.3
6.4
3.3

42.7

4.7

2.6
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II. Establishing Sense-Strand Specificity with HuR as a Positive Control
Previous data from our laboratory established ERBB2 expression is regulated by the
transcript stability factor HuR (Human Antigen R) (Scott et al., 2008). An in vitro binding assay
demonstrated that HuR is capable of binding to a radiolabelled probe consisting of the conserved
U-rich element of the ERBB2 3’UTR mRNA, established by the supershift induced in the HuRprobe complex (Fig. 13B). In addition, polysome fractions used in earlier experiments to
demonstrate decaying levels of ERBB2 mRNA upon TSA treatment were probed with HuR to
confirm that HuR was polyribosomally associated (Fig. 13D). As mentioned earlier, ERRB2
decay was shown to initiate on the polyribosome; therefore, we are searching for protein
candidates that could also associate with the polyribosome. Western blot analysis revealed that
high concentrations of HuR are found in the cytosol and notable amounts were found to be
associated with the polyribosomal fractions (Fig. 13E).
Results from mass spectrometry showed that HuR, also known as ELAV1, binds with a
2-fold higher specificity to the sense strand in comparison to the antisense strand (Table 1). We
used Western blot analysis to confirm that stability factors bind with greater affinity to the
coding strand of ERBB2 mRNA. As shown in Figure 13C, HuR bound to the sense strand in
both untreated and treated immunoprecipitates, but not to the antisense strand in the untreated
and treated immunnoprecipitates (Fig.13C). Due to the stable and non-differential expression of
HuR in both the treated and non-treated lanes, it serves as a positive control for the rest of the
immunoprecipitate data.
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Figure 13. ERBB2 expression is regulated by the transcript stability factor, HuR, which binds a conserved U-rich
element in the sense strand of the 3’ UTR of ERBB2 mRNA. A) Western Blot analysis, using immunoprecipitates
with sense vs. antisense 3’UTR ERBB2 mRNA constructs, reveals that HuR specifically binds to the sense strand of
the 3’UTR of ERBB2. B) 6-hour TSA-treated SKBR3 cell fractions demonstrating expression of ERBB2 mRNA in
fractions associated with the polysome. Same treated fractions in are probed with HuR on a Western Blot and shown
at the bottom. High concentrations are found in the cytosol and notable amounts are found in the polysomallyassociated fractions.
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III. Western Blot Analysis of Protein Candidates Identified b
by
y Mass Spectrometry
Peptidylprolyl isomerase A (PPIA), also known as cyclophilin A, was the strongest
protein candidate identified by mass spectrometry showing the greatest affinity to the sense
strand (Table 2). Studies have demonstrated its overexpression in several cancers, including
breast cancer (Hathout et al., 2002; Zheng et al., 2008). However, Western
estern blot analysis could
not confirm sense-strand specificity
city as seen by the lack of PPIA in the sense and antisense
regardless of treatment (Fig. 14).. Furthermore, Western blot analysis only recognized PPIA in
the cytoplasmic lysates but not the immunoprecipitates containing tthe
he ERBB2 mRNA construct
(Fig. 14A). Polysome profiling analysis also revealed that PPIA is not associated with the
polyribosome (Fig. 14B).

Figure 14. Western blot
lot analysis does not confirm mass spectrometry results for PPIA. A) Western blot analysis
using the CyPA antibody shows that PPIA is absence in both sense or antisense strands for control and 2-hour
2
TSAtreated immunoprecipitates. B) Western blot analysis shows that PPIA is not polyribosomally associated in
comparison to HuR, with the last notable signal ending in fra
fraction 7 for PPIA.

Probable ATP-dependent
dependent RNA helicase DDX5
DDX5, also known as p68, was another strong
protein candidate identified by mass spectrometry with a higher affinity to the sense strand
(Table 2). Studies have identified DDX5 as a required factor fo
forr cell proliferation in certain
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breast cancer cells (Mazurek et al., 2012)
2012).. Western blot analysis identified DDX5 binding to the
3’UTR of ERBB2 mRNA but specificity for the sense strand over the antisense could not be
confirmed (Fig. 15A). The non-treated
treated sense and antisense strands did show a difference in
intensity, with greater binding to the sense strand; however, the same difference in intensity was
not noted in the treated sense and antisense lanes. Looking at polysome profile analysis, DDX5
did show to be closer to the polyribosomal fractions than PPIA; however, there is a significant
drop off in signal after fraction 9 (Fig. 15
15B).

lot analysis partially confirms mass spectrometry results for DDX5
DDX5. A) Western blot analysis
Figure 15. Western blot
using the p68 antibody shows that DDX5 is present in both sense and antisense strands for control and 2-hour
2
TSAtreated immunoprecipitates. B) Western blot analysis shows that DDX5 may be polyribosomally associated
associate in
comparison to HuR, with the last notable
ble signal ending in fraction 9.
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Another weaker candidate, ribonuclease inhibitor 1 (RNH1), was tested using Western
blot analysis due to its role in HDACi resistance in certain cancers and its role in mRNA
turnover (Zhu et al., 2014). RNH1 was detecte
detected
d in our mass spectrometry analysis with a 1.8 fold
preferential binding to the sense strand. RACK1 is used to normalize for loading error in further
Western blots due to it strong association with the polysome and absence in cytoplasmic
fractions (Wilson-Edell, 2014). However, like PPIA, no signal could be detected in sense and
antisense lanes of the immunoprecipitates of both control aand 2-hour
hour TSA treatment (Fig. 16A).
16
We briefly looked at possible differential expression resultant of TSA treatment in polysomal
po
fractions since we were unable to investigate this in our pulldown. However, ppolysome
olysome profile
analysis confirmed that RNH1 is not associated with the polyribosome and is mainly present
pres in
cytosolic fractions (Fig. 16B).

RNH1 is a weak protein candidate involved in the ERBB2 decay
Figure 16. Western blot analysiss confirms that RNH
pathway. A) Western blot analysis shows that RNH1 is not present in the sense or antisense strands for control and
2-hour TSA-treated
treated immunoprecipitates. B) Western blot analysis shows that RNH1 is not polyribosomally
associated in comparison to RACK1, with the last notable signal ending in fraction 6 of the treated fractions.
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IV. hnRNP K as a Strong Candidate Mediating ERBB2 mRNA Stability
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is an essential RNA- and DNAbinding protein involved in gene expression and signal transduction including DNA
transcription, RNA splicing, RNA stability, and translation (Zhou et al., 2010). Several studies
have shown overexpression of hnRNP K in breast cancer and its importance in tumor cell
viability (Van Domselaar et al., 2012; Zhou et al., 2010). Mass spectrometry identified hnRNP K
with a three-fold difference in its specificity to the sense strand over the antisense strand (Table
1). Western blot analysis showed hnRNP K was present in both sense and antisense strands for
control and 2-hour TSA-treated immunoprecipitates (Fig. 17A). However, there was a notable
difference in intensity when comparing the sense strand of the control to that of the 2-hour TSAtreated lane. This was further investigated in Western blot analysis of polysome fractions (Fig.
17B). The results demonstrated that in addition to hnRNP K being polyribosomally associated, it
bound 3-times more strongly to TSA-treated fractions than control fractions (Fig. 17B). These
findings indicate that hnRNP K is a strong protein candidate mediating ERBB2 mRNA decay.
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lot analysis reveals hnRNP K as a strong protein candidate that shows differential binding to
Figure 17. Western blot
the 3’UTR of ERBB2 mRNA following TSA treatment and is polyribosomally associated. A) Western blot analysis
shows hnRNP K is present in both sense and antisense sstrands for control and 2-hour TSA-treated
treated
immunoprecipitates. However, a notable difference in intensity in the sense strand of the control and treated lanes
suggests that hnRNP K is involved in ERBB2 degradation following HDACi treatm
treatmet B) Western blot analysis
an
of
polysome fractions demonstrates hnRNP K is polyribosomally associated, shows 3 times greater binding to treated
fractions in comparison to control fractions as indicated by quantified expression levels below the blot.
blot

Based on this data, we wa
wanted
nted to further investigate expression patterns of hnRNP K in
extended polysome fractions to confirm its ribosomal association and differential expression
with TSA treatment. When comparing later polysome fractions (16+), there is a noticable
difference in the expression levels of hnRNP K in the control and 22-hour TSA-treated
treated fractions
(Fig. 18).. In the absence of treatment
treatment,, hnRNP K expression drops rapidly before the
polyribosomal fractions; however, in the presence of 22-hour
hour treatment with TSA, hnRNP K
expression
pression sustains itself to later polyribosomal
polyribosomally-associated fractions (Fig. 18A
A and C). When
charting the expression levels, the difference in expression levels between the control and treated
fractions are similar in early fractions, but after fraction 116,
6, the expression patterns are
significantly different (Fig. 18 B and D).
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Figure 18. 2-hour TSA treatment induces stronger hnRNP K expression in polyribosomally associated fractions. A)
Single Western blot analysis reveals relative expression of hnRNP K is similar in earlier monosomal fractions
regardless of treatment, but a 2 fold or greater expression is indicated in fractions treated with TSA that are
polyribosomally associated. B) Graphic analysis of data in part A uses hnRNPK/RACK1 expression ratio on the yaxis to visualize the significant difference of hnRNP K expression in fractions 21 and 23 following 2-hour treatment
with TSA. C) Extended Western blot analysis using later fractions measures the extent of hnRNP K in later
polyribosomal fractions. D) Graphic analysis of data in part C visualizes the stark drop-off of hnRNP K expression
in control fractions after 16, whereas 2-hour TSA-treated fractions sustain expression until fraction 34.
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DISCUSSION
We were able to identify differentially bound polyribosomal proteins to the coding-strand
sequence of the 3’UTR of ERBB2 mRNA, which helped uncover some candidates possibly
mediating HDACi induced decay of endogenously overexpressed ERBB2 transcripts in breast
cancer. hnRNP K demonstrated the most promising results in that its binding was significantly
altered after 2-hour TSA treatment in comparison to the control (Fig. 17 and 18). Previous
studies have illustrated that hnRNP K can be methylated at arginine residues, which plays a key
role in coordinating transcriptional responses to DNA damage as a cofactor for p53 (Chen et al.,
2008). Upon DNA damage, hnRNP K is shielded from MDM2-mediated proteasomal
degradation and then cooperates with p53 in transcriptional activation of cell-cycle arrest genes
(Moumen et al., 2005). Additionally, hnRNP K can be modified by both acetylation and
phosphorylation, strengthening the argument that HDACi treatment potentially induces hnRNP
K acetylation as part of the ERBB2 transcript decay mechanism (Enge et al., 2009). However,
further analysis of acetylation patterns of hnRNP K needs to be investigated.
With the amount of hnRNPs that were identified by mass spectrometry, it is likely that
hnRNPs form a complex, initiated by hnRNP K binding, to mediate ERBB2 mRNA decay.
hnRNPs are complexes of RNA and protein present in the cell nucleus during gene transcription
and subsequent post-transcriptional modification of mRNA (Han et al., 2013). They are known
to bind RNA polymerase II transcripts to form hnRNP particles, and these play functional roles
in DNA repair, telomere biogenesis, cell signaling, and gene expression regulation (Han et al.,
2013). The role of hnRNPs in mRNA stability and oncogene splicing are particular functions of
interest. Each hnRNP protein contains at least one RNA-binding motif and the adenylate plus the
uridylate-rich element (ARE) (Carpenter et al. 2006). They are commonly found in the 3'
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untranslated region (UTR) of mRNAs and mediate the degradation of cytokine and protooncogene mRNAs (Carpenter et al. 2006). In our case, these findings suggest that with the
abundance of hnRNPs present in our mass spectrometry analysis, several of these proteins may
form a complex and cooperate in mediating ERBB2 transcript decay. hnRNP K itself has been
shown to be part of several complexes that bind to the ERBB2 promoter, regulate metastasis at
the translational level, and promote tumorigenicity (Gumireddy et al., 2013; Sugimasa et al.,
2015; Zhang et al., 2012).
Nonetheless, when taking into account the abundance of data generated through mass
spectrometry, initial reports of sense-strand specific protein binding by mass spectrometry in
many cases, such as PPIA and RNH1, could not be confirmed by Western blot analysis. The
quality of the sample is the primary determinant for success in native mass spectrometry, and
sample heterogeneity due to partial protein degradation or the binding of adducts can severely
restrict the outcome of this technique (Van Duijn, 2010). Nonetheless, the use of mass
spectrometry in the future can also allow us to identify acetylation patterns of protein in addition
to their strand specificity. Another source of discrepancy for the Western blot results could
include the epitope specificity of antibodies used to detect the specific protein during Western
blot analysis coupled with the basic assumption that an exogenously supplied ERBB2 mRNA
construct can function similarly to an endogenously produced ERBB2 transcript. Additionally,
the in vitro results obtained in Figures 10-15 need to be verified by in vivo experiments to
confirm their reproducibility and significance as well as to evaluate the utility of a ERBB2
mRNA construct used in this study.
In order to translate the present findings into some therapeutic value in treating ERBB2positive breast cancers, further experiments will need to be conducted using an HDAC inhibitor
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that can be tested clinically instead of prototype tools, like TSA which is commonly used
experimentally due to its commercial availability but lacks good bioavailability so cannot be
used clinically. Currently, Panobinostat, developed by Novartis, is a pan-HDACi with the highest
inhibitory potency among clinically used hydroxamic acids, and clinical trials are looking at its
effectiveness in combination with transtuzumab to treat HER2-positive breast cancer (Dent et al.,
2009). In one study, patients who received 10 mg of Panobinostat three times weekly or 15 mg
of Panobinostat on days 1 and 8 of a 21-day cycle in combination with weekly Trastuzumab have
responded well to the treatment, and two of the patients have even shown a reduction in tumor
size (Conte et al., 2009). A structurally similar compound, Dacinostat, inhibits HDACs in
submicromolar concentrations and has demonstrated the ability to inhibit cell growth in addition
to inducing apoptosis (Dent et al., 2009). Also known as LAQ824, it has been shown to downregulate HER2 by depleting HER2 transcripts and promoted its degradation by the proteasome
(Fuino et al., 2003). Investigating the effects of these agents in place of TSA will help verify the
mechanism of HDACi induced ERBB2 decay in breast cancer patients.
Furthermore, development of transcript-targeted treatments coupled with small molecule
and receptor-disabling agents could lead to a highly successful strategy for overcoming
resistance to currently available receptor-targeted agents. Dacinostat was also shown to sensitize
human breast cancer cells to transtuzumab and other receptor disabling agents (Fuino et al.,
2003). Another study focused on the combination of Vorinostat, a pan-HDACi, and Tamoxifen
in breast cancer patients who progressed regardless of prior hormone therapy (Munster et al.,
2009). Hormone receptor signaling was disrupted with HDACi treatment, giving reason that
resistance to hormone receptor modulators is reversible (Dent et al., 2009). Studies have shown
that HDACi sensitizes ER-negative cell lines to Tamoxifen by inducing the release of HDAC1
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from the ERα-promoter, and in turn, restoring expression of ERα (Yang et al., 2001; Zhou et al.,
2007) or by activation of ERβ (Hodges-Gallagher et al., 2006), involving an upregulation or
translocation of ERβ (Duong et al., 2006; Jang et al., 2004). Six patients in this phase II study
responded well to the treatment with no resistance to the combination for longer than 6 months,
suggesting that this drug combination may help restore hormone sensitivity (Munster et al.,
2009). Progress in this effort could potentially lead to a cancer treatment strategy that is more
effective and selective, and less toxic, than the use of currently available pan-HDACi for the
treatment of ERBB2-overexpressing malignancies. Ultimately, advances in this research will
greatly improve the survival likelihood of patients suffering from ERBB2-positive breast cancer.
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APPENDIX 1
List of 42 protein candidates that displayed a 2 fold or greater binding to the sense strand over the antisense strand.

TBA1C
TBA1B
TBA1A
TIAR
PGD
OPA1
KHSRP
DNAJC10
LGALS3BP
DHX9
CCT2
SEC16A
CLTC
HSPA1A
ANXA6
ARF4
PDCD6
PDCD6IP
PSMB4
GGCT
PRDX2
PPIB
NME1
RPS9
RPS25
RPS19
RPS18
RPS16
RPS14
hnRNPM
hnRNPU1
hnRNPK
hnRNPU
hnRNPA1/B2
hnRNPH
hnRNPD
hnRNPA3
hnRNPA1
DDX3X
DDX5
PPIA
HuR
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APPENDIX 2
Complete list of protein binding to the 3’UTR of ERBB2 discovered during mass spectrometry.

Protein
10 kDa heat shock protein, mitochondrial
14-3-3 protein epsilon
2,4-dienoyl-CoA reductase, mitochondrial
26S proteasome non-ATPase regulatory subunit 11
26S proteasome non-ATPase regulatory subunit 13
26S proteasome non-ATPase regulatory subunit 3
28S ribosomal protein S16, mitochondrial
28S ribosomal protein S18b, mitochondrial
28S ribosomal protein S22, mitochondrial
28S ribosomal protein S26, mitochondrial
28S ribosomal protein S27, mitochondrial
28S ribosomal protein S29, mitochondrial
28S ribosomal protein S5, mitochondrial
28S ribosomal protein S6, mitochondrial
3-ketoacyl-CoA thiolase, mitochondrial
3-ketoacyl-CoA thiolase, peroxisomal
4-trimethylaminobutyraldehyde dehydrogenase
40S ribosomal protein S10
40S ribosomal protein S11
40S ribosomal protein S14
40S ribosomal protein S15a
40S ribosomal protein S16
40S ribosomal protein S18
40S ribosomal protein S19
40S ribosomal protein S2
40S ribosomal protein S20
40S ribosomal protein S21
40S ribosomal protein S25
40S ribosomal protein S28
40S ribosomal protein S3
40S ribosomal protein S3a
40S ribosomal protein S4, X isoform
40S ribosomal protein S6
40S ribosomal protein S7
40S ribosomal protein S9
40S ribosomal protein SA

Gene
HSPE1
YWHAE
DECR1
PSMD11
PSMD13
PSMD3
MRPS16
MRPS18B
MRPS22
MRPS26
MRPS27
DAP3
MRPS5
MRPS6
ACAA2
ACAA1
ALDH9A1
RPS10
RPS11
RPS14
RPS15A
RPS16
RPS18
RPS19
RPS2
RPS20
RPS21
RPS25
RPS28
RPS3
RPS3A
RPS4X
RPS6
RPS7
RPS9
RPSA
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4F2 cell-surface antigen heavy chain
6-phosphofructokinase type C
6-phosphofructokinase, liver type
6-phosphogluconate dehydrogenase, decarboxylating
60 kDa heat shock protein, mitochondrial
60S acidic ribosomal protein P0
60S acidic ribosomal protein P0-like
60S acidic ribosomal protein P2
60S ribosomal protein L11
60S ribosomal protein L12
60S ribosomal protein L17
60S ribosomal protein L18a
60S ribosomal protein L22
60S ribosomal protein L24
60S ribosomal protein L26-like 1
60S ribosomal protein L27
60S ribosomal protein L27a
60S ribosomal protein L28
60S ribosomal protein L3
60S ribosomal protein L30
60S ribosomal protein L31
60S ribosomal protein L34
60S ribosomal protein L35
60S ribosomal protein L38
60S ribosomal protein L4
60S ribosomal protein L5
60S ribosomal protein L6
60S ribosomal protein L7
60S ribosomal protein L7a
60S ribosomal protein L8
60S ribosomal protein L9
78 kDa glucose-regulated protein
Acetyl-CoA acetyltransferase, mitochondrial
Acidic leucine-rich nuclear phosphoprotein 32 family member A
Acidic leucine-rich nuclear phosphoprotein 32 family member B
Acidic leucine-rich nuclear phosphoprotein 32 family member C
Acidic leucine-rich nuclear phosphoprotein 32 family member D
Aconitate hydratase, mitochondrial
Actin-related protein 2/3 complex subunit 4
Actin-related protein 3
Actin-related protein 3B

SLC3A2
PFKP
PFKL
PGD
HSPD1
RPLP0
RPLP0P6
RPLP2
RPL11
RPL12
RPL17
RPL18A
RPL22
RPL24
RPL26L1
RPL27
RPL27A
RPL28
RPL3
RPL30
RPL31
RPL34
RPL35
RPL38
RPL4
RPL5
RPL6
RPL7
RPL7A
RPL8
RPL9
HSPA5
ACAT1
ANP32A
ANP32B
ANP32C
ANP32D
ACO2
ARPC4
ACTR3
ACTR3B
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Actin, alpha skeletal muscle
Actin, cytoplasmic 1
Actin, cytoplasmic 2
Activated RNA polymerase II transcriptional coactivator p15
Acyl-coenzyme A thioesterase 13
Acylamino-acid-releasing enzyme
Adenosine kinase
Adenosylhomocysteinase
ADP-ribosylation factor 1
ADP-ribosylation factor 4
ADP-ribosylation factor-like protein 8B
ADP/ATP translocase 1
ADP/ATP translocase 2
ADP/ATP translocase 3
ADP/ATP translocase 4
Alanine--tRNA ligase, cytoplasmic
Alcohol dehydrogenase [NADP(+)]
Aldehyde dehydrogenase, mitochondrial
Alpha-2-HS-glycoprotein
Alpha-enolase
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1
Annexin A11
Annexin A2
Annexin A5
Annexin A6
Annexin A7
Anterior gradient protein 2 homolog
AP-1 complex subunit beta-1
Apolipoprotein D
Arginase-1
Arginine--tRNA ligase, cytoplasmic
Argininosuccinate synthase
Aspartate aminotransferase, cytoplasmic
Aspartate aminotransferase, mitochondrial
ATP synthase subunit alpha, mitochondrial
ATP synthase subunit beta, mitochondrial
ATP-citrate synthase
ATP-dependent RNA helicase A
ATP-dependent RNA helicase DDX1
ATP-dependent RNA helicase DDX3X
Basic leucine zipper and W2 domain-containing protein 2

ACTA1
ACTB
ACTG1
SUB1
ACOT13
APEH
ADK
AHCY
ARF1
ARF4
ARL8B
SLC25A4
SLC25A5
SLC25A6
SLC25A31
AARS
AKR1A1
ALDH2
AHSG
ENO1
AIMP1
ANXA11
ANXA2
ANXA5
ANXA6
ANXA7
AGR2
AP1B1
APOD
ARG1
RARS
ASS1
GOT1
GOT2
ATP5A1
ATP5B
ACLY
DHX9
DDX1
DDX3X
BZW2
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Bifunctional glutamate/proline--tRNA ligase
Biliverdin reductase A
C-1-tetrahydrofolate synthase, cytoplasmic
CAD protein
Calmodulin-like protein 5
Calnexin
Calpain-2 catalytic subunit
Calumenin
Carbamoyl-phosphate synthase [ammonia], mitochondrial
Carbonyl reductase [NADPH] 1
Caspase-14
Cathepsin D
Citrate synthase, mitochondrial
Clathrin heavy chain 1
Clathrin light chain A
Clathrin light chain B
Coatomer subunit alpha
Cofilin-1
Constitutive coactivator of PPAR-gamma-like protein 1
Copine-3
Creatine kinase B-type
Creatine kinase U-type, mitochondrial
CTP synthase 1
Cyclin-dependent kinase 1
Cyclin-dependent kinase 12
Cyclin-dependent kinase 13
Cyclin-dependent kinase 14
Cyclin-dependent kinase 15
Cyclin-dependent kinase 16
Cyclin-dependent kinase 17
Cyclin-dependent kinase 18
Cyclin-dependent kinase 2
Cyclin-dependent kinase 20
Cyclin-dependent kinase 3
Cyclin-dependent kinase 4
Cyclin-dependent kinase 5
Cyclin-dependent kinase 6
Cyclin-dependent kinase 9
Cytosolic non-specific dipeptidase
D-3-phosphoglycerate dehydrogenase
D-dopachrome decarboxylase

EPRS
BLVRA
MTHFD1
CAD
CALML5
CANX
CAPN2
CALU
CPS1
CBR1
CASP14
CTSD
CS
CLTC
CLTA
CLTB
COPA
CFL1
FAM120A
CPNE3
CKB
CKMT1A
CTPS1
CDK1
CDK12
CDK13
CDK14
CDK15
CDK16
CDK17
CDK18
CDK2
CDK20
CDK3
CDK4
CDK5
CDK6
CDK9
CNDP2
PHGDH
DDT
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Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial
Dermcidin
Desmoplakin
Dihydrolipoyl dehydrogenase, mitochondrial
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate
dehydrogenase complex, mitochondrial
DNA-dependent protein kinase catalytic subunit
DNA-directed RNA polymerase II subunit RPB1
DNA-directed RNA polymerase II subunit RPB2
DNA-directed RNA polymerases I, II, and III subunit RPABC1
DnaJ homolog subfamily C member 10
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa
subunit
Dynamin-like 120 kDa protein, mitochondrial
E3 ubiquitin-protein ligase CHIP
E3 ubiquitin-protein ligase TRIM21
ELAV-like protein 1
Elongation factor 1-alpha 1
Elongation factor 1-alpha 2
Elongation factor 1-delta
Elongation factor 1-gamma
Elongation factor 2
Elongation factor Tu, mitochondrial
Endoplasmic reticulum resident protein 44
Endoplasmic reticulum-Golgi intermediate compartment protein 1
Endoplasmin
Epoxide hydrolase 1
Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-III
Eukaryotic peptide chain release factor subunit 1
Eukaryotic translation initiation factor 2 subunit 1
Eukaryotic translation initiation factor 2 subunit 2
Eukaryotic translation initiation factor 3 subunit A
Eukaryotic translation initiation factor 3 subunit C
Eukaryotic translation initiation factor 3 subunit E
Eukaryotic translation initiation factor 3 subunit F
Eukaryotic translation initiation factor 3 subunit I
Eukaryotic translation initiation factor 3 subunit J
Eukaryotic translation initiation factor 3 subunit L
Eukaryotic translation initiation factor 4 gamma 1
Exportin-2

ECH1
DCD
DSP
DLD
DLAT
PRKDC
POLR2A
POLR2B
POLR2E
DNAJC10
DDOST
OPA1
STUB1
TRIM21
ELAVL1
EEF1A1
EEF1A2
EEF1D
EEF1G
EEF2
TUFM
ERP44
ERGIC1
HSP90B1
EPHX1
EIF4A1
EIF4A3
ETF1
EIF2S1
EIF2S2
EIF3A
EIF3C
EIF3E
EIF3F
EIF3I
EIF3J
EIF3L
EIF4G1
CSE1L
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Ezrin
F-actin-capping protein subunit alpha-1
F-actin-capping protein subunit alpha-2
Far upstream element-binding protein 1
Far upstream element-binding protein 2
Farnesyl pyrophosphate synthase
Fatty acid synthase
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor 4
Fructose-bisphosphate aldolase A
Fumarate hydratase, mitochondrial
Fumarylacetoacetase
Galectin-3-binding protein
Galectin-7
Gamma-glutamylcyclotransferase
Gasdermin-A
Geranylgeranyl transferase type-2 subunit beta
Glucose-6-phosphate 1-dehydrogenase
Glucose-6-phosphate 1-dehydrogenase
Glucose-6-phosphate isomerase
Glutamine synthetase
Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1
Glutamine--tRNA ligase
Glutathione synthetase
Glyceraldehyde-3-phosphate dehydrogenase
Glycine--tRNA ligase
Glycogen debranching enzyme
Glycogen phosphorylase, brain form
Glyoxylate reductase/hydroxypyruvate reductase
GTP-binding protein SAR1b
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Guanine nucleotide-binding protein subunit beta-2-like 1
Guanine nucleotide-binding protein subunit beta-4
Heat shock 70 kDa protein 1A/1B
Heat shock cognate 71 kDa protein
Heat shock protein 105 kDa
Heat shock protein 75 kDa, mitochondrial

EZR
CAPZA1
CAPZA2
FUBP1
KHSRP
FDPS
FASN
FGFR1
FGFR2
FGFR3
FGFR4
ALDOA
FH
FAH
LGALS3BP
LGALS7
GGCT
GSDMA
RABGGTB
G6PD
G6PD
GPI
GLUL
GFPT1
QARS
GSS
GAPDH
GARS
AGL
PYGB
GRHPR
SAR1B
GNB1
GNB2
GNB3
GNB2L1
GNB4
HSPA1A
HSPA8
HSPH1
TRAP1
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Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Heterogeneous nuclear ribonucleoprotein A/B
Heterogeneous nuclear ribonucleoprotein A1
Heterogeneous nuclear ribonucleoprotein A1-like 2
Heterogeneous nuclear ribonucleoprotein A3
Heterogeneous nuclear ribonucleoprotein C-like 1
Heterogeneous nuclear ribonucleoprotein D-like
Heterogeneous nuclear ribonucleoprotein D0
Heterogeneous nuclear ribonucleoprotein F
Heterogeneous nuclear ribonucleoprotein H
Heterogeneous nuclear ribonucleoprotein H3
Heterogeneous nuclear ribonucleoprotein K
Heterogeneous nuclear ribonucleoprotein L
Heterogeneous nuclear ribonucleoprotein M
Heterogeneous nuclear ribonucleoprotein Q
Heterogeneous nuclear ribonucleoprotein R
Heterogeneous nuclear ribonucleoprotein U
Heterogeneous nuclear ribonucleoprotein U-like protein 1
Heterogeneous nuclear ribonucleoprotein U-like protein 2
Heterogeneous nuclear ribonucleoproteins A2/B1
Heterogeneous nuclear ribonucleoproteins C1/C2
Hexokinase-1
Histidine--tRNA ligase, cytoplasmic
Histone-arginine methyltransferase CARM1
Hypoxia up-regulated protein 1
Ig gamma-1 chain C region
Ig gamma-3 chain C region
Immunoglobulin lambda-like polypeptide 5
Importin subunit beta-1
Inorganic pyrophosphatase
Inorganic pyrophosphatase 2, mitochondrial
Inosine-5'-monophosphate dehydrogenase 1
Inosine-5'-monophosphate dehydrogenase 1
Inosine-5'-monophosphate dehydrogenase 2
Interleukin enhancer-binding factor 2
Interleukin enhancer-binding factor 3
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial
Isocitrate dehydrogenase [NADP] cytoplasmic
Isocitrate dehydrogenase [NADP], mitochondrial
Isoleucine--tRNA ligase, cytoplasmic

HSP90AA1
HSP90AB1
HNRNPAB
HNRNPA1
HNRNPA1L2
HNRNPA3
HNRNPCL1
HNRNPDL
HNRNPD
HNRNPF
HNRNPH1
HNRNPH3
HNRNPK
HNRNPL
HNRNPM
SYNCRIP
HNRNPR
HNRNPU
HNRNPUL1
HNRNPUL2
HNRNPA2B1
HNRNPC
HK1
HARS
CARM1
HYOU1
IGHG1
IGHG3
IGLL5
KPNB1
PPA1
PPA2
IMPDH1
IMPDH1
IMPDH2
ILF2
ILF3
IDH3A
IDH1
IDH2
IARS
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Keratinocyte proline-rich protein
L-lactate dehydrogenase A chain
L-lactate dehydrogenase B chain
La-related protein 1
Lamin-B2
LanC-like protein 1
Leucine--tRNA ligase, cytoplasmic
Lupus La protein
Lysine--tRNA ligase
Lysosome-associated membrane glycoprotein 1
Malate dehydrogenase, cytoplasmic
Malate dehydrogenase, mitochondrial
Methionine--tRNA ligase, cytoplasmic
mRNA cap guanine-N7 methyltransferase
Mucin-like protein 1
Multifunctional protein ADE2
Myosin light polypeptide 6
Myosin regulatory light polypeptide 9
Myosin-9
N-terminal kinase-like protein
NAD(P)H dehydrogenase [quinone] 1
NADP-dependent malic enzyme
Nascent polypeptide-associated complex subunit alpha
Neuroblast differentiation-associated protein AHNAK
Neutral alpha-glucosidase AB
Nicotinate phosphoribosyltransferase
Nitric oxide-associated protein 1
Non-POU domain-containing octamer-binding protein
Nuclear migration protein nudC
Nuclear protein localization protein 4 homolog
Nuclease-sensitive element-binding protein 1
Nucleolin
Nucleolysin TIA-1 isoform p40
Nucleolysin TIAR
Nucleophosmin
Nucleoside diphosphate kinase A
Obg-like ATPase 1
Ornithine aminotransferase, mitochondrial
Peflin
Peptidyl-prolyl cis-trans isomerase A
Peptidyl-prolyl cis-trans isomerase B

KPRP
LDHA
LDHB
LARP1
LMNB2
LANCL1
LARS
SSB
KARS
LAMP1
MDH1
MDH2
MARS
RNMT
MUCL1
PAICS
MYL6
MYL9
MYH9
SCYL1
NQO1
ME1
NACA
AHNAK
GANAB
NAPRT1
NOA1
NONO
NUDC
NPLOC4
YBX1
NCL
TIA1
TIAL1
NPM1
NME1
OLA1
OAT
PEF1
PPIA
PPIB
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Peptidyl-prolyl cis-trans isomerase FKBP4
Peroxiredoxin-1
Peroxiredoxin-2
Peroxiredoxin-5, mitochondrial
Peroxisomal acyl-coenzyme A oxidase 1
Phenylalanine--tRNA ligase alpha subunit
Phenylalanine--tRNA ligase beta subunit
Phosphatidylethanolamine-binding protein 1
Phosphoglucomutase-1
Phosphoglycerate kinase 1
Phosphoserine aminotransferase
Plasminogen activator inhibitor 1 RNA-binding protein
Plastin-2
Plastin-3
Poly [ADP-ribose] polymerase 1
Poly(rC)-binding protein 1
Polyadenylate-binding protein 1
Polyadenylate-binding protein 1-like
Polyadenylate-binding protein 4
Polyadenylate-binding protein 5
Polypyrimidine tract-binding protein 1
POTE ankyrin domain family member E
Pre-mRNA-processing factor 39
Prelamin-A/C
Probable ATP-dependent RNA helicase DDX17
Probable ATP-dependent RNA helicase DDX5
Profilin-1
Programmed cell death 6-interacting protein
Programmed cell death protein 6
Proliferating cell nuclear antigen
Proliferation-associated protein 2G4
Proliferation-associated protein 2G4
Proteasome subunit beta type-1
Proteasome subunit beta type-2
Proteasome subunit beta type-4
Proteasome subunit beta type-6
Protein arginine N-methyltransferase 1
Protein diaphanous homolog 1
Protein disulfide-isomerase
Protein disulfide-isomerase A3
Protein disulfide-isomerase A4

FKBP4
PRDX1
PRDX2
PRDX5
ACOX1
FARSA
FARSB
PEBP1
PGM1
PGK1
PSAT1
SERBP1
LCP1
PLS3
PARP1
PCBP1
PABPC1
PABPC1L
PABPC4
PABPC5
PTBP1
POTEE
PRPF39
LMNA
DDX17
DDX5
PFN1
PDCD6IP
PDCD6
PCNA
PA2G4
PA2G4
PSMB1
PSMB2
PSMB4
PSMB6
PRMT1
DIAPH1
P4HB
PDIA3
PDIA4
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Protein disulfide-isomerase A6
Protein DJ-1
Protein kinase C and casein kinase substrate in neurons protein 2
Protein S100-A6
Protein S100-A8
Protein S100-A9
Protein SEC13 homolog
Protein SET
Protein SETSIP
Protein Shroom3
Protein TFG
Protein transport protein Sec16A
Protein transport protein Sec23B
Protein transport protein Sec24A
Protein transport protein Sec24B
Protein transport protein Sec24C
Protein transport protein Sec24D
Protein transport protein Sec31A
Prothymosin alpha
Purine nucleoside phosphorylase
Putative 40S ribosomal protein S26-like 1
Putative annexin A2-like protein
Putative ATP-dependent RNA helicase DHX30
Putative elongation factor 1-alpha-like 3
Putative elongation factor 1-alpha-like 3
Putative heat shock protein HSP 90-beta 2
Putative protein FAM10A4
Putative protein FAM10A5
Putative synaptogyrin-2 like protein
Pyrroline-5-carboxylate reductase 1, mitochondrial
Pyrroline-5-carboxylate reductase 2
Pyruvate dehydrogenase E1 component subunit alpha, somatic form,
mitochondrial
Pyruvate kinase PKLR
Pyruvate kinase PKLR
Pyruvate kinase PKM
Rab GDP dissociation inhibitor beta
Ras GTPase-activating-like protein IQGAP1
Ras-related protein Rab-1B
Ras-related protein Rab-7a
Receptor tyrosine-protein kinase erbB-2

PDIA6
PARK7
PACSIN2
S100A6
S100A8
S100A9
SEC13
SET
SETSIP
SHROOM3
TFG
SEC16A
SEC23B
SEC24A
SEC24B
SEC24C
SEC24D
SEC31A
PTMA
PNP
RPS26P11
ANXA2P2
DHX30
EEF1A1P5
EEF1A1P5
HSP90AB2P
ST13P4
ST13P5
None
PYCR1
PYCR2
PDHA1
PKLR
PKLR
PKM
GDI2
IQGAP1
RAB1B
RAB7A
ERBB2
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Replication protein A 14 kDa subunit
Replication protein A 32 kDa subunit
Replication protein A 70 kDa DNA-binding subunit
Replication protein A 70 kDa DNA-binding subunit
Reticulon-4
Ribonuclease inhibitor
Ribose-phosphate pyrophosphokinase 1
Ribose-phosphate pyrophosphokinase 2
RNA-binding protein EWS
RNA-binding protein FUS
RuvB-like 1
Serine hydroxymethyltransferase, mitochondrial
Serine/threonine-protein kinase ICK
Serine/threonine-protein kinase MAK
Serpin B4
Serum albumin
Single-stranded DNA-binding protein, mitochondrial
Small nuclear ribonucleoprotein E
Small nuclear ribonucleoprotein Sm D2
Sodium/potassium-transporting ATPase subunit alpha-1
Sorcin
Sorting nexin-9
Spermidine synthase
Spliceosome RNA helicase DDX39B
Squamous cell carcinoma antigen recognized by T-cells 3
Src substrate cortactin
Staphylococcal nuclease domain-containing protein 1
Stress-70 protein, mitochondrial
Stress-induced-phosphoprotein 1
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial
Superoxide dismutase [Cu-Zn]
Synaptogyrin-2
T-complex protein 1 subunit alpha
T-complex protein 1 subunit beta
T-complex protein 1 subunit delta
T-complex protein 1 subunit epsilon
T-complex protein 1 subunit eta
T-complex protein 1 subunit gamma
T-complex protein 1 subunit theta
T-complex protein 1 subunit zeta
Tax1-binding protein 1

RPA3
RPA2
RPA1
RPA1
RTN4
RNH1
PRPS1
PRPS2
EWSR1
FUS
RUVBL1
SHMT2
ICK
MAK
SERPINB4
ALB
SSBP1
SNRPE
SNRPD2
ATP1A1
SRI
SNX9
SRM
DDX39B
SART3
CTTN
SND1
HSPA9
STIP1
SUCLG2
SOD1
SYNGR2
TCP1
CCT2
CCT4
CCT5
CCT7
CCT3
CCT8
CCT6A
TAX1BP1
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Thioredoxin
Thioredoxin domain-containing protein 5
Thioredoxin-dependent peroxide reductase, mitochondrial
Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1
Threonine--tRNA ligase, cytoplasmic
Thymidine phosphorylase
Transaldolase
Transcription activator BRG1
Transcription elongation factor SPT5
Transcriptional activator protein Pur-alpha
Transcriptional activator protein Pur-beta
Transcriptional adapter 2-beta
Transcriptional adapter 2-beta
Transferrin receptor protein 1
Transgelin-2
Transitional endoplasmic reticulum ATPase
Transketolase
Trifunctional enzyme subunit alpha, mitochondrial
Tripartite motif-containing protein 3
tRNA (cytosine(34)-C(5))-methyltransferase
tRNA selenocysteine 1-associated protein 1
tRNA-splicing ligase RtcB homolog
Tubulin alpha-1A chain
Tubulin alpha-1B chain
Tubulin alpha-1C chain
Tubulin alpha-3E chain
Tubulin beta chain
Tubulin beta-1 chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-3 chain
Tubulin beta-4A chain
Tubulin beta-4B chain
Tubulin beta-6 chain
Tubulin beta-8 chain
Tubulin-specific chaperone A
Tyrosine-protein kinase Blk
Tyrosine-protein kinase Fgr
Tyrosine-protein kinase Fyn
Tyrosine-protein kinase HCK
Tyrosine-protein kinase Lck

TXN
TXNDC5
PRDX3
TSTD1
TARS
TYMP
TALDO1
SMARCA4
SUPT5H
PURA
PURB
TADA2B
TADA2B
TFRC
TAGLN2
VCP
TKT
HADHA
TRIM3
NSUN2
TRNAU1AP
RTCB
TUBA1A
TUBA1B
TUBA1C
TUBA3E
TUBB
TUBB1
TUBB2A
TUBB2B
TUBB3
TUBB4A
TUBB4B
TUBB6
TUBB8
TBCA
BLK
FGR
FYN
HCK
LCK
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Tyrosine-protein kinase Lyn
Tyrosine-protein kinase Yes
U1 small nuclear ribonucleoprotein A
Ubiquitin carboxyl-terminal hydrolase 13
Ubiquitin-like modifier-activating enzyme 1
UDP-glucose:glycoprotein glucosyltransferase 1
UTP--glucose-1-phosphate uridylyltransferase
Vacuolar protein sorting-associated protein 35
Valine--tRNA ligase
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial
Vesicle-trafficking protein SEC22b
Vinculin
WD repeat-containing protein 1
WD repeat-containing protein 61
X-ray repair cross-complementing protein 5
X-ray repair cross-complementing protein 6
YTH domain-containing family protein 2
Zinc-alpha-2-glycoprotein

LYN
YES1
SNRPA
USP13
UBA1
UGGT1
UGP2
VPS35
VARS
ACADVL
SEC22B
VCL
WDR1
WDR61
XRCC5
XRCC6
YTHDF2
AZGP1
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